Indian Journal of Urology
RESEARCH ARTICLE
Year
: 2003  |  Volume : 19  |  Issue : 2  |  Page : 113--116

Doxazocin in management of benign prostatic hyperplasia


NK Mohanty, RP Arora, AK Jha, S Singh Pal 
 Department of Urology, Safdarjang Hospital, New Delhi, India

Correspondence Address:
N K Mohanty
D-11/87, West Kidwai Nagar, New Delhi - 110 023
India

A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve­ment of 90% in their symptoms at the end of the study with an increase of maximum flow rate (MFR) by 5-5.5 ml/sec and average flow rate (AFR) 2.5-3 ml/sec. Adverse effects were minimum and patient compliance was very good with good drug tolerability. Our study strongly supports the use of doxazocin as an alternative in the management of uncomplicated BPH with hypertension.


How to cite this article:
Mohanty N K, Arora R P, Jha A K, Pal S S. Doxazocin in management of benign prostatic hyperplasia.Indian J Urol 2003;19:113-116


How to cite this URL:
Mohanty N K, Arora R P, Jha A K, Pal S S. Doxazocin in management of benign prostatic hyperplasia. Indian J Urol [serial online] 2003 [cited 2021 Aug 1 ];19:113-116
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=113;epage=116;aulast=Mohanty;type=0